When was Mighty Therapeutics founded?

Mighty Therapeutics was founded in 2005 and raised its 1st funding round 21 years after it was founded.

Where is Mighty Therapeutics located?

Mighty Therapeutics is headquartered in Needham, United States.

Is Mighty Therapeutics a funded company?

Mighty Therapeutics is a funded company, having raised a total of $25M across 2 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Jul 14, 2026.

When was the latest funding round of Mighty Therapeutics?

Mighty Therapeutics' latest funding was a $***** Series B round on Jul 14, 2026, with participation from 1 investor. Its primary sector is Diversified Pharmaceuticals. In United States, the Diversified Pharmaceuticals sector has seen $585M in funding in 2026 to date.

Where does Mighty Therapeutics rank among its competitors?

Mighty Therapeutics ranks 214th amongst 1826 active competitors, of which 94 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Mighty Therapeutics, which secured $125M in Jul, 2026.

Who are the top competitors of Mighty Therapeutics?

Mighty Therapeutics' top competitors include AbbVie, Gilead and Amgen. Among them, Mighty Therapeutics secured the most recent funding round in July, 2026.

Mighty Therapeutics - 2026 Company Profile, Funding & Competitors

Company Details

Developer of therapies targeting diseases associated with mitochondrial dysfunction. Research focuses on addressing bioenergetic deficits linked to rare genetic conditions, ophthalmic disorders, and neurodegenerative diseases. Therapeutic programs aim to treat conditions characterized by muscle weakness, visual impairment, and progressive neurological decline.

Website: mightytx.com
Email ID: *****@mightytx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2005

Location

Needham, United States

Stage

Series B

Total Funding

$25M in 2 rounds

Latest Funding Round

Series B, Jul 14, 2026, $*****

Investors

K2 HealthVentures & 1 more

Ranked

214^th among 1826 active competitors

Similar Companies

AbbVie & 1853 more

View Mighty Therapeutics' full profile

Mighty Therapeutics has raised a total funding of $25M over 2 rounds. Its first funding round was on Jul 14, 2026. Its latest funding round was a Series B round on Jul 14, 2026 for $*****. 1 investor participated in its latest round. Mighty Therapeutics has 2 institutional investors.

Here is the list of recent funding rounds of Mighty Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 14, 2026	8520877	Series B	9602588	2212723	2182027	3346921
Jul 14, 2026	4692186	Conventional Debt	4642449	1424976	7341155	K2 HealthVentures

Access funding benchmarks and valuations. Sign up today!

View details of Mighty Therapeutics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mighty Therapeutics include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Mighty Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 9 others	83/100
2nd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	Jindal ventures, Seaside Private Capital ... & 17 others	81/100
3rd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	79/100
4th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	76/100
5th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
6th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	74/100
7th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
8th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	70/100
9th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, Triodos Investment Management ... & 11 others	70/100
10th	Genentech 1976, San Francisco (United States), Acquired	R&D company focused on manufacturing drugs for multiple therapeutic areas	$72.5M	Ignite 500, The Column Group & 4 others	69/100
214th	Mighty Therapeutics 2005, Needham (United States), Series B	Developer of therapies targeting diseases associated with mitochondrial dysfunction	$25M	K2 HealthVentures, Morningside	33/100